Cargando…
Primary treatment of diabetic macular edema
Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmace...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685231/ https://www.ncbi.nlm.nih.gov/pubmed/19503772 |
_version_ | 1782167304164868096 |
---|---|
author | Ranchod, Tushar M Fine, Stuart L |
author_facet | Ranchod, Tushar M Fine, Stuart L |
author_sort | Ranchod, Tushar M |
collection | PubMed |
description | Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF). Surgical treatment has been shown to be appropriate in selected cases. We review the evidence and scientific rationale for various primary treatment options in patients with DME. Regular and timely ophthalmologic evaluation remains crucial to recognition and treatment of macular edema in diabetic patients. |
format | Text |
id | pubmed-2685231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26852312009-06-05 Primary treatment of diabetic macular edema Ranchod, Tushar M Fine, Stuart L Clin Interv Aging Review Diabetic macular edema (DME) is a leading cause of vision loss in older Americans. Thermal laser treatment remains the mainstay of treatment for DME. Recently, alternative primary treatments for DME have been evaluated. These treatments include intravitreal injections of steroids as well as pharmaceuticals containing antibodies against vascular endothelial growth factor (VEGF). Surgical treatment has been shown to be appropriate in selected cases. We review the evidence and scientific rationale for various primary treatment options in patients with DME. Regular and timely ophthalmologic evaluation remains crucial to recognition and treatment of macular edema in diabetic patients. Dove Medical Press 2009 2009-05-14 /pmc/articles/PMC2685231/ /pubmed/19503772 Text en © 2009 Ranchod and Fine, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Ranchod, Tushar M Fine, Stuart L Primary treatment of diabetic macular edema |
title | Primary treatment of diabetic macular edema |
title_full | Primary treatment of diabetic macular edema |
title_fullStr | Primary treatment of diabetic macular edema |
title_full_unstemmed | Primary treatment of diabetic macular edema |
title_short | Primary treatment of diabetic macular edema |
title_sort | primary treatment of diabetic macular edema |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2685231/ https://www.ncbi.nlm.nih.gov/pubmed/19503772 |
work_keys_str_mv | AT ranchodtusharm primarytreatmentofdiabeticmacularedema AT finestuartl primarytreatmentofdiabeticmacularedema |